ea0035p577 | Endocrine tumours and neoplasia | ECE2014
Ruszniewski Philippe
, Caplin Martyn
, Valle Juan
, Lombard-Bohas Catherine
, Poston Graeme
, Perros Petros
, Holubec Lubos
, Fave Gianfranco Delle
, Smith Denis
, Niccoli Patricia
, Maisonobe Pascal
, Atlan Philippe
Introduction: Somatostatin analogues are widely used to reduce the incidence and severity of carcinoid syndrome symptoms. However, their impact on patients’ satisfaction with symptom control needs further investigation. SYMNET was a large international multicentre observation study that assessed PROs during LAN-ATG treatment of carcinoid syndrome in gastroenteropancreatic neuroendocrine tumour (GEP–NET) patients.Methods: At routine clinic visit...